Skip to main content
MENU
Program
Agenda
CE Information
Educational Supporters
Speakers
Exhibit & Sponsor
Exhibitor Information
Sponsors & Supporters
Plan Your Experience
New York City
Dallas
Media & PR
Press Information
Media Center
Register
REGISTER NOW
Watch Video
More Debates & Deeper Analysis
connect with us
Agenda
+
Available Dates
April 27-28 | New York City
October 5-6 | Dallas
October 5-6 | Dallas
|
View upcoming dates
REGISTER NOW
MENU
Agenda
October 5-6 | Dallas
Available Dates
Register
April 27-28 | New York City
October 5-6 | Dallas
Saturday October 05, 2024
8:00 AM – 8:05 AM
Welcome
Co-Chair
Corey Langer
MD, FACP
Edward Garon
MD, MS
8:05 AM – 8:20 AM
Debate: Handling Stage 3: Surgical vs. Non-Surgical Approach - Surgical Approach
Presenter
Kemp Kernstine
MD, PhD
8:20 AM – 8:35 AM
Debate: Handling Stage 3: Surgical vs. Non-Surgical Approach - Non-Surgical Approach
Presenter
Puneeth Iyengar
MD, PhD
8:35 AM – 8:45 AM
Debate: Handling Stage 3: Surgical vs. Non-Surgical Approach - DISCUSSION
Panelist
Kemp Kernstine
MD, PhD
Puneeth Iyengar
MD, PhD
8:45 AM – 9:00 AM
Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - YES
Presenter
Jason Porter
MD
9:00 AM – 9:15 AM
Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - NO
Presenter
Natalie Vokes
MD
9:15 AM – 9:25 AM
Debate: PD-L1 <1%: Is This the Place for CTLA-4 Inhibition in Lung Cancer? - DISCUSSION
Panelist
Jason Porter
MD
Natalie Vokes
MD
9:25 AM – 9:35 AM
Break
9:35 AM – 10:35 AM
Non-CME Innovation Theater - Sponsored by Catalyst
10:35 AM – 11:15 AM
Recognizing and Managing Lambert-Eaton Myasthenic Syndrome Associated with Small Cell Lung Cancer
Presenter
Jennifer Carlisle
MD
11:15 AM – 11:30 AM
Debate: KRAS Inhibitors Are Standard Second-Line - YES
Presenter
Kathryn Arbour
MD
11:30 AM – 11:45 AM
Debate: KRAS Inhibitors Are Standard Second-Line - NO
Presenter
Shirish Gadgeel
MD
11:45 AM – 11:55 AM
Debate: KRAS Inhibitors Are Standard Second-Line - DISCUSSION
Panelist
Kathryn Arbour
MD
Shirish Gadgeel
MD
11:55 AM – 12:05 PM
Break
12:05 PM – 1:05 PM
Non-CME Innovation Theater - Sponsored by DSI
1:05 PM – 1:35 PM
Exhibit Hall
1:35 PM – 2:15 PM
Targeting HER2-Mutant NSCLC: A Focus on Biomarker Testing and Targeted Therapies
Presenter
Lyudmila Bazhenova
MD
2:15 PM – 2:30 PM
Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - Primetime
Presenter
Jyoti Malhotra
MD, MPH
2:30 PM – 2:45 PM
Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - Need More Time
Presenter
Salma Jabbour
MD
2:45 PM – 2:55 PM
Debate: STK11 and Associated Biomarkers: Ready for Primetime or Need More Time? - DISCUSSION
Panelist
Jyoti Malhotra
MD, MPH
Salma Jabbour
MD
2:55 PM – 3:10 PM
Break
3:10 PM – 3:25 PM
Debate: ADCs in Wild Type mNSCLC: The New Emperor or the Emperor’s New Clothes - The New Emperor
Presenter
Arjan Gower
MD, MS
3:25 PM – 3:40 PM
Debate: ADCs in Wild Type mNSCLC: The New Emperor or the Emperor’s New Clothes - The Emperor’s New Clothes
Presenter
Corey Langer
MD, FACP
3:40 PM – 3:50 PM
Debate: ADCs in Wild Type mNSCLC: The New Emperor or the Emperor’s New Clothes - DISCUSSION
Panelist
Arjan Gower
MD, MS
Corey Langer
MD, FACP
3:50 PM – 4:05 PM
Debate: Mesothelioma: Is There a Role for Surgery? - PROs
Presenter
Neel Chudgar
MD
4:05 PM – 4:20 PM
Debate: Mesothelioma: Is There a Role for Surgery? - CONs
Presenter
Hedy Kindler
MD
4:20 PM – 4:30 PM
Debate: Mesothelioma: Is There a Role for Surgery? - DISCUSSION
Panelist
Hedy Kindler
MD
Neel Chudgar
MD
Sunday October 06, 2024
8:30 AM – 8:35 AM
Welcome
Co-Chair
Corey Langer
MD, FACP
Edward Garon
MD, MS
8:35 AM – 8:50 AM
Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - YES
Presenter
Jay Lee
MD
8:50 AM – 9:05 AM
Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - NO
Presenter
David Gerber
MD
9:05 AM – 9:15 AM
Debate: Is There a Role for Adjuvant After Neoadjuvant Immunotherapy? - DISCUSSION
Panelist
David Gerber
MD
Jay Lee
MD
9:15 AM – 9:30 AM
Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - TKIs
Presenter
Mary Fidler
MD
9:30 AM – 9:45 AM
Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - Immunotherapy
Presenter
Lyudmila Bazhenova
MD
9:45 AM – 9:55 AM
Debate: Front-Line c-MET or BRAF Mutations: TKIs vs Immunotherapy - DISCUSSION
Panelist
Lyudmila Bazhenova
MD
Mary Fidler
MD
9:55 AM – 10:25 AM
Exhibit Hall
10:25 AM – 11:05 AM
EGFR Gene Mutations in Non-Small Cell Lung Cancer: Updates on Targeted Strategies
Presenter
Sawsan Rashdan
11:05 AM – 11:20 AM
Debate: Should Liquid Biopsies Be Part of Initial Workup? - YES
Presenter
Hatim Husain
MD
11:20 AM – 11:35 AM
Debate: Should Liquid Biopsies Be Part of Initial Workup? - NO
Presenter
Kurt Schalper
MD, PhD
11:35 AM – 11:45 AM
Debate: Should Liquid Biopsies Be Part of Initial Workup? - DISCUSSION
Panelist
Hatim Husain
MD
Kurt Schalper
MD, PhD
11:45 AM – 12:30 PM
Lunch
12:30 PM – 1:10 PM
Large Cell Neuroendocrine Carcinoma of the Lung: Addressing Diagnostic Challenges and Understanding Current and Emerging Therapies
Presenter
Aman Chauhan
MD
1:10 PM – 1:25 PM
Debate: Is There a Programmed Role for Local Ablative Therapy in Metastatic Disease? - PROS
Presenter
Puneeth Iyengar
MD, PhD
1:25 PM – 1:40 PM
Debate: Is There a Programmed Role for Local Ablative Therapy in Metastatic Disease? - CONS
Presenter
Drew Moghanaki
MD, MPH
1:40 PM – 1:50 PM
Debate: Is There a Programmed Role for Local Ablative Therapy in Metastatic Disease? - DISCUSSION
Panelist
Drew Moghanaki
MD, MPH
Puneeth Iyengar
MD, PhD
1:50 PM – 2:05 PM
Debate: Is There a Continuing Role for Angiogenesis Inhibition in Recurrent or Metastatic NSCLC? - PROS
Presenter
Edward Garon
MD, MS
2:05 PM – 2:20 PM
Debate: Is There a Continuing Role for Angiogenesis Inhibition in Recurrent or Metastatic NSCLC? - CONS
Presenter
Helen Ross
MD
2:20 PM – 2:30 PM
Debate: Is There a Continuing Role for Angiogenesis Inhibition in Recurrent or Metastatic NSCLC? - DISCUSSION
Panelist
Edward Garon
MD, MS
Helen Ross
MD
Questions?
Contact